

The Executive Office of Health & Human Services

Pharmacy and Therapeutics Committee Meeting Minutes

Tuesday, September 12, 2023

8:00 AM

Gainwell Technologies

Location: OHHS Virks Building, 3 West Rd, Cranston, RI



P & T Members Present: Todd Brothers, PharmD
Nickolai Morin, PharmD
Bill Quirk, RPh
Matt Salisbury, MD
Rick Wagner, MD
Tracey Taviera, PharmD

Absent: Greg Allen, MD
Jerry Fingerut, MD, Medical Director, (EOHHS)
Karen Mariano, RPh (Gainwell Technologies)

Others Present: Ann Bennett, MHSA (Gainwell Technologies)
Maryanne Guertin, RPh (Gainwell Technologies)
Kathryn Novak, RPh (Magellan Medicaid Administration)

The meeting was called to order by the Chairperson once a quorum was in attendance - 8:10 am. Chairman Tracey Taviera called the meeting to order and asked for introductions the committee and those supporting the meeting. The previous meeting minutes were reviewed and by vote were accepted as presented.

Public testimony included the following speakers and topics.

Follow up information should be sent to karen.mariano@gainwelltechnologies.com for distribution to the committee.

P & T Speakers	Affiliation	Topic
Tyson Thompson	Pfizer	Nurtec ODT
Mark Douglas	Braeburn Pharmaceuticals	Brixaldi
Annie	AbbVie	Qulipta and Ubrelvy

Magellan Medicaid Administration (MMA) presented the following categories for therapeutic class reviews with discussion from the pharmacy and therapeutics committee.

Therapeutic Categories				Vote: Yac	Vote: N/n	Abstain	Motion
Antimigraine agents	Triptans	Oral, Nasal, Subcutaneous	No changes recommended	5	0	0	Passes
	Other	Spray	New product Zavzpret discussed, a calcitonin gene-related peptide (CGRP) receptor antagonist. Not indicated for the preventive treatment of migraine. Ubrelyvy change to non-preferred. Nurtec ODT change to preferred.	5	0	0	Passes
Analgesics	Long Acting	Transdermal, oral	Commentary: Updated CDC clinical practice guidelines and FDA updates for opioid pain medications. Black box warning for IR and ER regarding life threatening respiratory depression and concomitant use with benzodiazepines and other CNS depressants. Tramadol higher strength (100mg) and ER/SR on nonpreferred; tramadol lower strength(50mg) and tramadol/apap on preferred. Question Increased utilization past COVID? To find out and follow up. Number of deaths from Fentanyl and deaths from BZD to follow up December meeting. Xtampza ER change to preferred. Butrans low compliance due to wrap around.	5	0	0	Passes
Analgesics	Short Acting	Oral	Nucynta- FDA grants New Patient Population exclusivity pediatric patients aged 6 years and older with a body weight of at least 40 kg. Commentary: tramadol lower dose(50mg) and tramadol/apap on preferred PDL. Change to nonpreferred to discuss at next meeting.	5	0	0	Passes
NSAIDS		Oral	Celecoxib and diclofenac potassium change to preferred. Flurbiprofen and ketorolac change to nonpreferred.	5	0	0	Passes
Opiate Dependence Treatments		Sublingual, Injection, Nasal, Oral	New product information. Brixadi a new dosage form of the partial opioid agonist buprenorphine. Suboxone low compliance due to wraparound and generic being dispensed at pharmacy instead of brand. Naloxone RX/OTC switch approved for full movement from legend to otc. Currently Narcan not on OTC coverage list for RI. Need to have discussion once it moves forward to put on RI OTC list. Currently leave on PDL.	5	0	0	Passes

Continued categories for therapeutic class reviews.

Therapeutic Categories				Vote: Yes	Vote: No	Abstain	Motion
Skeletal Muscle Relaxants		Oral	Recommend tizanidine capsules as preferred.	5	0	0	Passes
Ophthalmics	Allergic Conjunctivitis	Ophthalmic	No changes recommended.	5	0	0	Passes
	Antibiotics	Ophthalmic	Recommend sulfacetamide solution to non-preferred	5	0	0	Passes
	Antibiotic-Steroid Combo	Ophthalmic	No changes recommended. Commentary: Tobradex not in compliance due to wraparound	5	0	0	Passes
	Anti-inflammatories	Ophthalmic	Recommend Durazol to nonpreferred	5	0	0	Passes
	Anti-inflammatories/immunomodulator	Ophthalmic	No changes recommended.	5	0	0	Passes
	Glaucoma agents	Ophthalmic	Lumigan 2.5 mL, 5mL, 7.5mL recommended as preferred. New product information Lyuzeh and Vuity	5	0	0	Passes
Otics	Anti-inflammatory	Otic	No changes recommended.	5	0	0	Passes
	Antibiotics	Otic	No changes recommended	5	0	0	Passes
	Anti-infectives and anesthetics	Otic	No changes recommended	5	0	0	Passes
Bladder Relaxant Preparations		Oral	Gelnique manufacturer decided to discontinue product. No changes recommended.	5	0	0	Passes
BPH Treatments		Oral	No changes recommended.	5	0	0	Passes
Uterine Disorder Treatment		Oral	No changes recommended.	5	0	0	Passes
Botulinum toxins		Intramuscular	No changes recommended. Compliance with Dysport due to wraparound	5	0	0	Passes

2023 Schedule
December 12th

2024 Schedule
April 9
June 4
September 10
December 10

Adjournment
The meeting adjourned at 9:12am.

